BCM
NXTC icon

BML Capital Management’s NextCure NXTC Stock Holding History

BML Capital Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,795
Closed -$131K – 26
2025
Q1 		$131K Hold
22,795
– – 0.11% 24
2024
Q4 		$211K Sell
22,795
-244
-1% -$3.59K 0.13% 22
2024
Q3 		$379K Hold
23,039
– – 0.22% 27
2024
Q2 		$440K Sell
23,039
-2,500
-10% -$48.6K 0.31% 26
2024
Q1 		$683K Hold
25,539
– – 0.45% 27
2023
Q4 		$349K Hold
25,539
– – 0.26% 34
2023
Q3 		$395K Hold
25,539
– – 0.36% 22
2023
Q2 		$552K Hold
25,539
– – 0.5% 24
2023
Q1 		$454K Buy
+25,539
New +$492K 0.39% 27

Other funds holding NXTC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CPA
Cardiff Park Advisors Carlsbad, California $1.25B AUM 24.12% 1-Year Est. Return

BML Capital Management's NXTC Position: Q2 2025 in Review

BML Capital Management sold out of NextCure (NXTC) in Q2 2025, closing a stake of 22,795 shares — an estimated $131K sold.

BML Capital Management first reported a position in NXTC in Q1 2023 and held it in 9 quarters. The position peaked at $683K in Q1 2024. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2025.

  • BML Capital Management reported no remaining NextCure position as of Q2 2025 after selling out during the quarter.
  • BML Capital Management sold 22,795 NextCure shares in Q2 2025, an estimated $131K.
  • BML Capital Management first reported a position in NextCure in Q1 2023 and held it in 9 quarters.
  • BML Capital Management's NextCure position peaked at $683K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2025.

Based on BML Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.